Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 245

1.

Economic Analysis of Vaccination Programs.

Mauskopf J, Standaert B, Connolly MP, Culyer AJ, Garrison LP, Hutubessy R, Jit M, Pitman R, Revill P, Severens JL.

Value Health. 2018 Oct;21(10):1133-1149. doi: 10.1016/j.jval.2018.08.005. Review.

PMID:
30314613
2.

Cost-Effectiveness Analysis in Telehealth: A Comparison between Home Telemonitoring, Nurse Telephone Support, and Usual Care in Chronic Heart Failure Management.

Grustam AS, Severens JL, De Massari D, Buyukkaramikli N, Koymans R, Vrijhoef HJM.

Value Health. 2018 Jul;21(7):772-782. doi: 10.1016/j.jval.2017.11.011. Epub 2018 Mar 21.

PMID:
30005749
3.

Comparison of EQ-5D and SF-36 in untreated patients with symptoms of intermittent claudication.

Vaidya A, Kleinegris MC, Severens JL, Ramaekers BL, Ten Cate-Hoek AJ, Ten Cate H, Joore MA.

J Comp Eff Res. 2018 Jun;7(6):535-548. doi: 10.2217/cer-2017-0029. Epub 2018 Jun 1.

PMID:
29855189
4.

Integrating clinical and economic evidence in clinical guidelines: More needed than ever!

Knies S, Severens JL, Brouwer WBF.

J Eval Clin Pract. 2018 Apr 26. doi: 10.1111/jep.12936. [Epub ahead of print]

PMID:
29700903
5.

Socioeconomic benefit to individuals of achieving 2020 targets for four neglected tropical diseases controlled/eliminated by innovative and intensified disease management: Human African trypanosomiasis, leprosy, visceral leishmaniasis, Chagas disease.

Lenk EJ, Redekop WK, Luyendijk M, Fitzpatrick C, Niessen L, Stolk WA, Tediosi F, Rijnsburger AJ, Bakker R, Hontelez JAC, Richardus JH, Jacobson J, Le Rutte EA, de Vlas SJ, Severens JL.

PLoS Negl Trop Dis. 2018 Mar 13;12(3):e0006250. doi: 10.1371/journal.pntd.0006250. eCollection 2018 Mar.

6.

Health care input constraints and cost effectiveness analysis decision rules.

van Baal P, Morton A, Severens JL.

Soc Sci Med. 2018 Mar;200:59-64. doi: 10.1016/j.socscimed.2018.01.026. Epub 2018 Jan 28.

7.

What are the images used to diagnose and assess suspected strokes?: A systematic literature review of care in four European countries.

Peultier AC, Redekop K, Coche E, Severens JL.

Expert Rev Pharmacoecon Outcomes Res. 2018 Apr;18(2):177-189. doi: 10.1080/14737167.2018.1429270. Epub 2018 Feb 5. Review.

PMID:
29400089
8.

Care coordination in a business-to-business and a business-to-consumer model for telemonitoring patients with chronic diseases.

Grustam AS, Vrijhoef H, Cordella A, Koymans R, Severens JL.

Int J Care Coord. 2017 Dec;20(4):135-147. doi: 10.1177/2053434517747908. Epub 2017 Dec 14.

9.

Early warning systems for the management of chronic heart failure: a systematic literature review of cost-effectiveness models.

Albuquerque De Almeida F, Al M, Koymans R, Caliskan K, Kerstens A, Severens JL.

Expert Rev Pharmacoecon Outcomes Res. 2018 Apr;18(2):161-175. doi: 10.1080/14737167.2018.1417841. Epub 2017 Dec 19. Review.

PMID:
29235882
10.

Assessment of a Business-to-Consumer (B2C) model for Telemonitoring patients with Chronic Heart Failure (CHF).

Grustam AS, Vrijhoef HJM, Koymans R, Hukal P, Severens JL.

BMC Med Inform Decis Mak. 2017 Oct 11;17(1):145. doi: 10.1186/s12911-017-0541-2.

11.

Influence of disease activity on RA treatment choices in countries with restricted access to expensive, innovative drugs: a discrete choice experiment among rheumatologists.

Hifinger M, Hiligsmann M, Ramiro S, Watson V, Berghea F, Péntek M, Keat A, Severens JL, Fautrel B, Boonen A.

RMD Open. 2017 Sep 4;3(2):e000453. doi: 10.1136/rmdopen-2017-000453. eCollection 2017.

12.

What determines the effects and costs of breast cancer screening? A protocol of a systematic review of reviews.

Mandrik O, Ekwunife OI, Zielonke N, Meheus F, Severens JL, Lhachimi SK, Murillo R.

Syst Rev. 2017 Jun 28;6(1):122. doi: 10.1186/s13643-017-0510-y.

13.

Epidemiology and Management of Atrial Fibrillation and Stroke: Review of Data from Four European Countries.

Ceornodolea AD, Bal R, Severens JL.

Stroke Res Treat. 2017;2017:8593207. doi: 10.1155/2017/8593207. Epub 2017 May 28. Review.

14.

Response to Letter to the Editor Regarding "Abiraterone Acetate for the Treatment of Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal".

Ramaekers BLT, Riemsma R, Tomini F, van Asselt T, Deshpande S, Duffy S, Armstrong N, Severens JL, Kleijnen J, Joore MA.

Pharmacoeconomics. 2017 Jun;35(6):665-667. doi: 10.1007/s40273-017-0507-3. No abstract available.

PMID:
28391508
15.

Chemotherapy for ovarian cancer in the Netherlands: a population-based study on treatment patterns and outcomes.

Houben E, van Haalen HG, Sparreboom W, Overbeek JA, Ezendam NP, Pijnenborg JM, Severens JL, van Herk-Sukel MP.

Med Oncol. 2017 Apr;34(4):50. doi: 10.1007/s12032-017-0901-x. Epub 2017 Feb 21.

PMID:
28224447
16.

The Socioeconomic Benefit to Individuals of Achieving the 2020 Targets for Five Preventive Chemotherapy Neglected Tropical Diseases.

Redekop WK, Lenk EJ, Luyendijk M, Fitzpatrick C, Niessen L, Stolk WA, Tediosi F, Rijnsburger AJ, Bakker R, Hontelez JA, Richardus JH, Jacobson J, de Vlas SJ, Severens JL.

PLoS Negl Trop Dis. 2017 Jan 19;11(1):e0005289. doi: 10.1371/journal.pntd.0005289. eCollection 2017 Jan.

17.

Patients' preferences and economic considerations play an important role in treatment decisions: a discrete choice experiment among rheumatologists.

Hifinger M, Hiligsmann M, Ramiro S, Severens JL, Fautrel B, Watson V, Boonen A.

Rheumatology (Oxford). 2017 Jan;56(1):68-76. doi: 10.1093/rheumatology/kew328. Epub 2016 Oct 22.

PMID:
28028156
18.

Cost-effectiveness analysis of new generation coronary CT scanners for difficult-to-image patients.

Burgers LT, Redekop WK, Al MJ, Lhachimi SK, Armstrong N, Walker S, Rothery C, Westwood M, Severens JL.

Eur J Health Econ. 2017 Jul;18(6):731-742. doi: 10.1007/s10198-016-0824-z. Epub 2016 Sep 20.

PMID:
27650359
19.

Abiraterone Acetate for the Treatment of Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer: An Evidence Review Group Perspective of an NICE Single Technology Appraisal.

Ramaekers BLT, Riemsma R, Tomini F, van Asselt T, Deshpande S, Duffy S, Armstrong N, Severens JL, Kleijnen J, Joore MA.

Pharmacoeconomics. 2017 Feb;35(2):191-202. doi: 10.1007/s40273-016-0445-5. Review.

20.

Economic considerations and patients' preferences affect treatment selection for patients with rheumatoid arthritis: a discrete choice experiment among European rheumatologists.

Hifinger M, Hiligsmann M, Ramiro S, Watson V, Severens JL, Fautrel B, Uhlig T, van Vollenhoven R, Jacques P, Detert J, Canas da Silva J, Scirè CA, Berghea F, Carmona L, Péntek M, Keat A, Boonen A.

Ann Rheum Dis. 2017 Jan;76(1):126-132. doi: 10.1136/annrheumdis-2016-209202. Epub 2016 May 17.

PMID:
27190098
21.

Reply to T. Magnes et al.

Deenen MJ, Cats A, Severens JL, Beijnen JH, Schellens JH.

J Clin Oncol. 2016 Jul 10;34(20):2434-5. doi: 10.1200/JCO.2016.67.4374. Epub 2016 May 9. No abstract available.

PMID:
27161961
22.

Cost-effectiveness of Elective Endovascular Aneurysm Repair Versus Open Surgical Repair of Abdominal Aortic Aneurysms.

Burgers LT, Vahl AC, Severens JL, Wiersema AM, Cuypers PW, Verhagen HJ, Redekop WK.

Eur J Vasc Endovasc Surg. 2016 Jul;52(1):29-40. doi: 10.1016/j.ejvs.2016.03.001. Epub 2016 Apr 23.

23.

Added Prognostic Value of Cerebrospinal Fluid Biomarkers in Predicting Decline in Memory Clinic Patients in a Prospective Cohort.

Handels RL, Joore MA, Vos SJ, Aalten P, Ramakers IH, Rikkert MO, Scheltens P, Jansen WJ, Visser PJ, van Berckel BM, van Domburg P, Smid M, Hoff E, Hoogmoed J, Bouwman F, Claassen J, Leentjens AF, Wolfs CA, Severens JL, Verhey FR.

J Alzheimers Dis. 2016 Mar 31;52(3):875-85. doi: 10.3233/JAD-151120.

PMID:
27031483
24.

Productivity Loss Related to Neglected Tropical Diseases Eligible for Preventive Chemotherapy: A Systematic Literature Review.

Lenk EJ, Redekop WK, Luyendijk M, Rijnsburger AJ, Severens JL.

PLoS Negl Trop Dis. 2016 Feb 18;10(2):e0004397. doi: 10.1371/journal.pntd.0004397. eCollection 2016 Feb. Review.

25.

Using meta-regression analyses in addition to conventional systematic review methods to examine the variation in cost-effectiveness results - a case study.

Burgers LT, van de Wetering FT, Severens JL, Redekop WK.

BMC Health Serv Res. 2016 Jan 20;16:23. doi: 10.1186/s12913-015-1230-4. Review.

26.

Treatment variation in stent choice in patients with stable or unstable coronary artery disease.

Burgers LT, McClellan EA, Hoefer IE, Pasterkamp G, Jukema JW, Horsman S, Pijls NH, Waltenberger J, Hillaert MA, Stubbs AC, Severens JL, Redekop WK.

Neth Heart J. 2016 Feb;24(2):110-9. doi: 10.1007/s12471-015-0783-5.

27.

Upfront Genotyping of DPYD*2A to Individualize Fluoropyrimidine Therapy: A Safety and Cost Analysis.

Deenen MJ, Meulendijks D, Cats A, Sechterberger MK, Severens JL, Boot H, Smits PH, Rosing H, Mandigers CM, Soesan M, Beijnen JH, Schellens JH.

J Clin Oncol. 2016 Jan 20;34(3):227-34. doi: 10.1200/JCO.2015.63.1325. Epub 2015 Nov 16.

PMID:
26573078
28.

Implementation of Population Dynamics In Modelling Health And Budget Impact of An Intervention for A Chronic Disease With Multiple Disease Subtypes.

Tran-Duy A, Boonen A, Caro JJ, Severens JL.

Value Health. 2015 Nov;18(7):A700. doi: 10.1016/j.jval.2015.09.2618. Epub 2015 Oct 20. No abstract available.

29.

Including Human Resource Constraints In Health Economic Evaluations.

Thongkong N, van Baal P, Severens JL.

Value Health. 2015 Nov;18(7):A688. doi: 10.1016/j.jval.2015.09.2552. Epub 2015 Oct 20. No abstract available.

30.

Economic Evaluation of Targeted Antifungal Treatment Sequencing Strategies For Invasive Aspergillosis Based on Real World Data: The Case of Dutch Clinical Practice.

Buyukkaramikli N, van Agthoven M, Leunis A, Severens JL.

Value Health. 2015 Nov;18(7):A586. doi: 10.1016/j.jval.2015.09.1493. Epub 2015 Oct 20. No abstract available.

31.

The Cost-Effectiveness Analysis of Philips Motiva Telehealth System: A Comparison Between Home Telemonitoring, Nurse Telephone Support And Usual Care In Chronic Heart Failure.

Grustam AS, Severens JL, de Massari D, Koymans R, Vrijhoef H.

Value Health. 2015 Nov;18(7):A358. doi: 10.1016/j.jval.2015.09.681. Epub 2015 Oct 20. No abstract available.

32.
33.

Cost-effectiveness of adding rituximab to fludarabine and cyclophosphamide for treatment of chronic lymphocytic leukemia in Ukraine.

Mandrik O, Corro Ramos I, Knies S, Al M, Severens JL.

Cancer Manag Res. 2015 Aug 25;7:279-89. doi: 10.2147/CMAR.S79258. eCollection 2015.

34.

Lenalidomide for the Treatment of Low- or Intermediate-1-Risk Myelodysplastic Syndromes Associated with Deletion 5q Cytogenetic Abnormality: An Evidence Review of the NICE Submission from Celgene.

Blommestein HM, Armstrong N, Ryder S, Deshpande S, Worthy G, Noake C, Riemsma R, Kleijnen J, Severens JL, Al MJ.

Pharmacoeconomics. 2016 Jan;34(1):23-31. doi: 10.1007/s40273-015-0318-3.

35.

Costs of Hospital Stay in Specialized Diabetic Foot Department in Russia.

Ignatyeva VI, Severens JL, Ramos IC, Galstyan GR, Avxentyeva MV.

Value Health Reg Issues. 2015 Sep;7:80-86. doi: 10.1016/j.vhri.2015.09.003. Epub 2015 Nov 14.

PMID:
29698156
36.

Use of quality checklists and need for disease-specific guidance in economic evaluations: a meta-review.

Frederix GW, Severens JL, Hövels AM.

Expert Rev Pharmacoecon Outcomes Res. 2015;15(4):675-85. doi: 10.1586/14737167.2015.1069185. Review.

PMID:
26176753
37.

Economic value of in vitro fertilization in Ukraine, Belarus, and Kazakhstan.

Mandrik O, Knies S, Severens JL.

Clinicoecon Outcomes Res. 2015 Jun 12;7:347-56. doi: 10.2147/CEOR.S79513. eCollection 2015.

38.

[Threshold value for reimbursement of costs of new drugs: cost-effectiveness research and modelling are essential links].

Frederix GW, Hövels AM, Severens JL, Raaijmakers JA, Schellens JH.

Ned Tijdschr Geneeskd. 2015;159:A7728. Review. Dutch.

PMID:
26083839
39.

Early cost-utility analysis of general and cerebrospinal fluid-specific Alzheimer's disease biomarkers for hypothetical disease-modifying treatment decision in mild cognitive impairment.

Handels RL, Joore MA, Tran-Duy A, Wimo A, Wolfs CA, Verhey FR, Severens JL.

Alzheimers Dement. 2015 Aug;11(8):896-905. doi: 10.1016/j.jalz.2015.02.009. Epub 2015 Jun 9.

40.

The influence of preferred place of birth on the course of pregnancy and labor among healthy nulliparous women: a prospective cohort study.

van Haaren-ten Haken TM, Hendrix M, Smits LJ, Nieuwenhuijze MJ, Severens JL, de Vries RG, Nijhuis JG.

BMC Pregnancy Childbirth. 2015 Feb 14;15:33. doi: 10.1186/s12884-015-0455-x.

41.

REVIEWING TRANSFERABILITY IN ECONOMIC EVALUATIONS ORIGINATING FROM EASTERN EUROPE.

Mandrik O, Knies S, Kalo Z, Severens JL.

Int J Technol Assess Health Care. 2015;31(6):434-41. doi: 10.1017/S0266462315000677. Review.

42.

Economic evaluation of implementation strategies in health care.

Hoomans T, Severens JL.

Implement Sci. 2014 Dec 18;9:168. doi: 10.1186/s13012-014-0168-y.

43.

Real world cost of human epidermal receptor 2-positive metastatic breast cancer patients: a longitudinal incidence-based observational costing study in the Netherlands and Belgium.

Frederix GW, Severens JL, Hövels AM, van Hasselt JG, Hooiveld MJ, Neven P, Raaijmakers JA, Schellens JH.

Eur J Cancer Care (Engl). 2015 May;24(3):340-54. doi: 10.1111/ecc.12266. Epub 2014 Nov 21.

PMID:
25413216
44.

Literature Review of Decision-Analytical Models Used in the Economic Evaluation of Empirical/Targeted Antifungal Treatments for Invasive Fungal Infections.

Buyukkaramikli NC, Gaultney J, Leunis A, Severens JL.

Value Health. 2014 Nov;17(7):A636. doi: 10.1016/j.jval.2014.08.2285. Epub 2014 Oct 26. No abstract available.

45.

IMTA Productivity Cost Questionnaire (IPCQ).

Bouwmans C, Krol M, Brouwer W, Severens JL, Koopmanschap MA, Hakkaart L.

Value Health. 2014 Nov;17(7):A550. doi: 10.1016/j.jval.2014.08.1791. Epub 2014 Oct 26. No abstract available.

46.

Do the Us Panel Recommendations Hold for Europe? Investigating the Relation Between Quality of Life Versus Work-Status, Absenteeism and Presenteeism.

Knies S, Boonen A, Severens JL.

Value Health. 2014 Nov;17(7):A549. doi: 10.1016/j.jval.2014.08.1786. Epub 2014 Oct 26. No abstract available.

47.

Transferability of Economic Evaluations To Central and Eastern Euroepan and Former Soviet Countries.

Mandrik O, Knies S, Kaló Z, Severens JL.

Value Health. 2014 Nov;17(7):A443-4. doi: 10.1016/j.jval.2014.08.1172. Epub 2014 Oct 26. No abstract available.

48.

Cost-effectiveness of risk assessment and tailored treatment for peripheral arterial disease patients.

Vaidya A, Joore MA, ten Cate-Hoek AJ, ten Cate H, Severens JL.

Biomark Med. 2014;8(8):989-99. doi: 10.2217/bmm.14.45.

PMID:
25343671
49.

Optimizing the use of expert panel reference diagnoses in diagnostic studies of multidimensional syndromes.

Handels RL, Wolfs CA, Aalten P, Bossuyt PM, Joore MA, Leentjens AF, Severens JL, Verhey FR.

BMC Neurol. 2014 Oct 4;14:190. doi: 10.1186/s12883-014-0190-3.

50.

Is it cost-effective to use a test to decide which individuals with an intermediate cardiovascular disease risk would benefit from statin treatment?

Burgers LT, Nauta ST, Deckers JW, Severens JL, Redekop WK.

Int J Cardiol. 2014 Oct 20;176(3):980-7. doi: 10.1016/j.ijcard.2014.08.134. Epub 2014 Sep 2.

PMID:
25217221

Supplemental Content

Loading ...
Support Center